The Food and Drug Administration proposed Monday to let companies lawfully sell products containing N-acetyl-L-cysteine, or NAC, as dietary supplements if they meet the other requirements for supplements. Some NAC products are already on store shelves under a temporary FDA enforcement policy. The proposal would put their eligibility into a regulation if the agency finalizes it.

The FDA announcement came Nov. 16. The Federal Register’s public inspection copy is scheduled for publication Nov. 17. The FDA says it will keep its current policy for certain NAC products in place while the proposal moves through rulemaking.

Why some NAC products can already be bought

A bottle labeled N-Acetyl Cysteine
An NAC product labeled as a dietary supplement in August 2015.Patrick Pelletier / Wikimedia Commons · CC BY-SA 4.0

The FDA says it first approved NAC as a drug in 1963, before the agency found evidence that it had been marketed as a food or dietary supplement. Federal law generally excludes an ingredient from the dietary supplement definition when it was first approved as a drug and was not previously marketed as a food or supplement. The law also gives the FDA a way to make an exception by regulation after notice and public comment.

Two groups asked the FDA in 2021 to reconsider its position. One petition also asked the agency to pursue a formal rule if it kept its original interpretation of the law. The Council for Responsible Nutrition, a supplement industry trade group and one of the petitioners, documented its challenge to the agency’s position. The FDA maintained the exclusion in its March 2022 response and later issued guidance saying it generally did not intend to enforce it against NAC products labeled as dietary supplements if the products would otherwise meet the law. Other violations remained subject to enforcement.

That approach kept a market open even though the exclusion stayed in place. In a preliminary economic analysis, the agency found sales of more than 115,000 bottles or containers in 2023 in the data it examined. The FDA described the figure as a lower bound because its data did not cover the full market.

What the proposed rule would change

A different bottle displaying the words N-Acetyl-L-Cysteine
An NAC supplement bottle photographed in April 2025.Vack Xu / Wikimedia Commons · CC0 1.0

The FDA would add NAC to a new regulation listing ingredients that are exempt from the exclusion. The agency says this is the first time it has proposed to use that rulemaking authority. The proposal would also specify that adding NAC to a dietary supplement would no longer violate a separate provision that restricts adding certain drugs to food, including dietary supplements.

If the proposal becomes final, the agency says it intends to withdraw the 2022 guidance. The regulation would apply to NAC. Manufacturers would still have to follow the rules for product labeling and manufacturing, and a supplement label could not lawfully claim to treat a disease simply because the ingredient became eligible. The FDA says its review did not identify safety concerns with the proposed use of NAC as a dietary supplement. That review concerns the ingredient’s eligibility. The FDA’s consumer guidance explains that supplements do not go through the same advance approval for safety and effectiveness as drugs.

How to comment on the proposal

The proposed notice identifies the public docket as FDA-2025-N-2699. It says the FDA will take comments for 60 days after Federal Register publication, with online comments due by 11:59 p.m. Eastern on the closing day. The public inspection copy leaves the calendar deadline blank. Once the notice publishes, check the date on the Federal Register listing and use the docket number on Regulations.gov to find the submission page.

The notice says online comments and attachments are made public as submitted. It gives separate instructions for paper submissions that contain confidential information, including how to send a public copy with sensitive details removed. The FDA will consider comments before deciding whether to issue a final rule.